Merck closes $10.8B deal with Prometheus
Merck closed its $10.8 billion acquisition of Prometheus Biosciences, setting the stage for the drugmaker’s pursuit of an immunology blockbuster.
In a news release on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
